Abstract
Alzheimers disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.
Keywords: Glycosphingolipids, ganglioside, presenilin, neurotrophin, Trk, lipid rafts, cholesterol, familial Alzheimer's disease
CNS & Neurological Disorders - Drug Targets
Title: Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
Volume: 5 Issue: 4
Author(s): Tatsuro Mutoh, Yoshio Hirabayashi, Takateru Mihara, Madoka Ueda, Hiroshi Koga, Akihiro Ueda, Takako Kokura and Hiroko Yamamoto
Affiliation:
Keywords: Glycosphingolipids, ganglioside, presenilin, neurotrophin, Trk, lipid rafts, cholesterol, familial Alzheimer's disease
Abstract: Alzheimers disease (AD) is a devastating neurodegenerative disorder dividing into two forms, early onset familial and late onset sporadic forms. Early onset genetic cases (familial AD (FAD)) constitute about 10% of all AD cases. Heretofore, highly fibrillinogenic and pathological Aβ peptide formation is regarded as the fundamental molecular basis for this disorder. Recent enormous efforts to find out a pathogenesis, however, have revealed that this disorder has a multiplicity of causes such as glycosphingolipids abnormalities, impairment of neurotrophin signaling, protein trafficking, and protein turnover. Most of these aspects were disclosed by the studies on FAD-related presenilin. In this review, we will focus on the current knowledge of many abnormal aspects of cellular lipids, especially glycosphingolipids other than a pathogenic Aβ production caused by the mutant presenilins as a model system. Moreover, we will discuss how these glycosphingolipids abnormalities cause the pathological conditions found in this disorder.
Export Options
About this article
Cite this article as:
Mutoh Tatsuro, Hirabayashi Yoshio, Mihara Takateru, Ueda Madoka, Koga Hiroshi, Ueda Akihiro, Kokura Takako and Yamamoto Hiroko, Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2006; 5 (4) . https://dx.doi.org/10.2174/187152706777950710
DOI https://dx.doi.org/10.2174/187152706777950710 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Alzheimers Disease and Immunotherapy
Current Alzheimer Research Meet Our Editorial Board Member
Current Medicinal Chemistry NMNAT Expression and its Relation to NAD Metabolism
Current Medicinal Chemistry The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease
Current Drug Metabolism Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology Editorial: Neurodegenerative Disorders: Synthesis, Drug Delivery Strategies and Biological Evaluation of New Therapeutic Agents
Central Nervous System Agents in Medicinal Chemistry Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles
Current Gene Therapy Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review
Current Topics in Medicinal Chemistry The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Current Medicinal Chemistry Targeting Conserved Pathways: Mitochondrial Dysfunction and Beyond
Current Neurovascular Research Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design